Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

Endocyte (NASDAQ:ECYT), and ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced a supply agreement under which ITM will supply to Endocyte the medical radioisotope no-carrier-added (n.c.a.) lutetium (¹⁷⁷Lu), EndolucinBeta^®, to support clinical supply of ¹⁷⁷Lu-PSMA-617 for the phase 3 VISION trial expected to be initiated by Endocyte in the second quarter of 2018.

As quoted in the press release:

“ITM has been an innovator in the development of the highly purified form of lutetium-177, an integral component of the ¹⁷⁷Lu-PSMA-617 therapy for the investigational treatment of prostate cancer,” said Mike Sherman, president and CEO of Endocyte. “We have made a strategic decision to utilize EndolucinBeta^® because of its favorable properties which will be important due to ¹⁷⁷Lu-PSMA-617’s significant potential market opportunity and widespread use. We are pleased to announce this agreement with ITM which will be key to the effective execution of our phase 3 VISION trial.”

Click here to read the full press release.